CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Dr. Jain brings extensive experience in the biotech and pharma sectors and has been instrumental in driving innovation, vaccine development, and healthcare advancement
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
